These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 32765834)

  • 1. Drug Therapies for the Management of Sickle Cell Disease.
    Rai P; Ataga KI
    F1000Res; 2020; 9():. PubMed ID: 32765834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sickle Cell Disease: A Review.
    Kavanagh PL; Fasipe TA; Wun T
    JAMA; 2022 Jul; 328(1):57-68. PubMed ID: 35788790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Evolving Landscape of Drug Therapies for Sickle Cell Disease.
    Rai P; Desai PC; Ataga KI
    Hematol Oncol Clin North Am; 2022 Dec; 36(6):1285-1312. PubMed ID: 36400544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Red Blood Cells as Therapeutic Target to Treat Sickle Cell Disease.
    Bhatt S; Argueta DA; Gupta K; Kundu S
    Antioxid Redox Signal; 2024 Jun; 40(16-18):1025-1049. PubMed ID: 37975291
    [No Abstract]   [Full Text] [Related]  

  • 5. Emerging disease-modifying therapies for sickle cell disease.
    Carden MA; Little J
    Haematologica; 2019 Sep; 104(9):1710-1719. PubMed ID: 31413089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An update review of new therapies in sickle cell disease: the prospects for drug combinations.
    Lugthart S; Ginete C; Kuona P; Brito M; Inusa BPD
    Expert Opin Pharmacother; 2024 Feb; 25(2):157-170. PubMed ID: 38344818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using disease-modifying therapies in sickle cell disease.
    Rai P; Ataga KI
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):519-531. PubMed ID: 38066905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the Treatment of Sickle Cell Disease.
    Kapoor S; Little JA; Pecker LH
    Mayo Clin Proc; 2018 Dec; 93(12):1810-1824. PubMed ID: 30414734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sickle cell disease: progress towards combination drug therapy.
    Pace BS; Starlard-Davenport A; Kutlar A
    Br J Haematol; 2021 Jul; 194(2):240-251. PubMed ID: 33471938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incorporation of novel therapies for the management of sickle cell disease: A pharmacist's perspective.
    Dela-Pena JC; King MA; Brown J; Nachar VR
    J Oncol Pharm Pract; 2022 Apr; 28(3):646-663. PubMed ID: 35060419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. l-glutamine, crizanlizumab, voxelotor, and cell-based therapy for adult sickle cell disease: Hype or hope?
    Leibovitch JN; Tambe AV; Cimpeanu E; Poplawska M; Jafri F; Dutta D; Lim SH
    Blood Rev; 2022 May; 53():100925. PubMed ID: 34991920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in Sickle Cell Disease Treatments.
    Pavan AR; Dos Santos JL
    Curr Med Chem; 2021; 28(10):2008-2032. PubMed ID: 32520675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing the Safety and Efficacy of L-Glutamine, Voxelotor, and Crizanlizumab for Reducing the Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease: A Systematic Review.
    Dick MH; Abdelgadir A; Kulkarni VV; Akram H; Chatterjee A; Pokhrel S; Khan S
    Cureus; 2022 May; 14(5):e24920. PubMed ID: 35706735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evolving treatment landscape for children with sickle cell disease.
    Jacob SA; Talati R; Kanter J
    Lancet Child Adolesc Health; 2023 Nov; 7(11):797-808. PubMed ID: 37858508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxyurea for children with sickle cell disease in sub-Saharan Africa: A summary of the evidence, opportunities, and challenges.
    Dexter D; McGann PT
    Pharmacotherapy; 2023 May; 43(5):430-441. PubMed ID: 36906823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene Therapies for Sickle Cell Disease.
    Weaver SB; Singh D; Wilson KM
    J Pharm Technol; 2024 Oct; 40(5):236-247. PubMed ID: 39391326
    [No Abstract]   [Full Text] [Related]  

  • 17. National trends in hospitalizations for sickle cell disease in the United States following the FDA approval of hydroxyurea, 1998-2008.
    Okam MM; Shaykevich S; Ebert BL; Zaslavsky AM; Ayanian JZ
    Med Care; 2014 Jul; 52(7):612-8. PubMed ID: 24926708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging drugs for the treatment of sickle cell disease: a review of phase II/III trials.
    Ross JM; Forté S; Soulières D
    Expert Opin Emerg Drugs; 2022 Jun; 27(2):211-224. PubMed ID: 35912835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advancements in Sickle Cell Disease (SCD) Treatment: A Review of Novel Pharmacotherapies and Their Impact on Patient Outcomes.
    Khan SJ; Zaidi SAT; Murtaza SF; Asif M; Kumar V
    Cureus; 2023 Aug; 15(8):e42847. PubMed ID: 37664319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Voxelotor: A Novel Treatment for Sickle Cell Disease.
    Herity LB; Vaughan DM; Rodriguez LR; Lowe DK
    Ann Pharmacother; 2021 Feb; 55(2):240-245. PubMed ID: 32674605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.